Arbutus to Participate at JMP Securities Life Sciences Conference
June 13 2019 - 8:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that Dr. Michael Sofia and Dr. Gaston Picchio will
participate in a fireside chat at JMP Securities Life Sciences
Conference at 10:00 am ET on Thursday, June 20, 2019.
A live webcast of the fireside chat can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com. A replay of the webcast will be
available for 90 days following the live
presentations.
About Arbutus
Arbutus Biopharma Corporation is a
publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated
to discovering, developing, and commercializing a cure for patients
suffering from chronic Hepatitis B infection. Arbutus is developing
multiple drug candidates, each of which have the potential to
improve upon the standard of care and contribute to a curative
combination regimen. For more information, visit
www.arbutusbio.com.
Contact Information
Investors
Mark MurrayPresident and CEOPhone: 604-419-3200 Email:
ir@arbutusbio.com
Pam Murphy Investor Relations ConsultantPhone:
604-419-3200Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024